Trials / Withdrawn
WithdrawnNCT06232707
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alnuctamab | Specified dose on specified days |
| DRUG | Pomalidomide | Specified dose on specified days |
| DRUG | Daratumumab | Specified dose on specified days |
| DRUG | Elotuzumab | Specified dose on specified days |
| DRUG | Carfilzomib | Specified dose on specified days |
| DRUG | Dexamethasone | Specified dose on specified days |
Timeline
- Start date
- 2024-05-03
- Primary completion
- 2025-11-16
- Completion
- 2030-09-21
- First posted
- 2024-01-31
- Last updated
- 2024-05-31
Locations
170 sites across 27 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Norway, Portugal, Romania, South Korea, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06232707. Inclusion in this directory is not an endorsement.